Report cover image

Sarcopenia Marketed and Pipeline Drugs Assessment, Clinical Trials, Social Media and Competitive Landscape, 2022 Update

Publisher GlobalData
Published Mar 29, 2022
Length 58 Pages
SKU # GBDT17223070

Description

Sarcopenia Marketed and Pipeline Drugs Assessment, Clinical Trials, Social Media and Competitive Landscape, 2022 Update

Summary

This reports provides a data-driven overview of the current and future competitive landscape in Sarcopenia therapeutics.

Synopsis
  • There are 51 million cases of sarcopenia in the 16 countries covered in GlobalData’s epidemiology forecast for sarcopenia.
  • There is no FDA approved marketed product for the treatment of sarcopenia.
  • The sarcopenia pipeline consists of 41 pharmaceuticals spanning all stages of development. However, none of these molecules are present in the late-stage pipeline.
  • Non-industrial sponsors dominate clinical trial development in sarcopenia, with the US emerging as the key country for conducting trials in sarcopenia.
  • Deals involving licensing sarcopenia assets are the most common type of deal globally.
  • With the current sarcopenia market being completely untapped, there remains a lot of potential for new market entrants.
    • Scope

    GlobalData’s Sarcopenia Marketed and Pipeline Drugs Assessment, Clinical Trials, Social Media and Competitive Landscape, 2022 Update combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

    Components of the report include -
  • Disease Landscape
  • Disease Overview
  • Epidemiology Overview
  • Treatment Overview
  • Marketed Products Assessment
  • Pipeline Assessment
  • Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
  • Late-to-mid-stage Pipeline Drugs
  • Phase Transition Success Rate and Likelihood of Approval
  • Clinical Trials Assessment
  • Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
  • Enrolment Analytics, Site Analytics, Feasibility Analysis
  • Deals Landscape
  • Mergers, Acquisitions, and Strategic Alliances by Region
  • Overview of Recent Deals
  • Commercial Assessment
  • Key Market Players
  • Future Market Catalysts
    • Reasons to Buy
    • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
    • Develop business strategies by understanding the trends shaping and driving the Sarcopenia market.
    • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Sarcopenia market in the future.
    • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
    • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
    • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

    Table of Contents

    58 Pages
    • Key Findings
    • Disease Overview
      • Epidemiology Overview - Total Prevalent Cases of Sarcopenia in 2022 and 2027
      • Treatment Guidelines
      • Marketed Drugs - Leading Marketed Drugs in Sarcopenia
      • Pipeline Drugs Overview - Phase II and Phase I Pipeline Drugs in Sarcopenia
      • Pipeline Drugs - Overview by Development Stage
      • Pipeline Drugs - Overview by Molecule Type
      • Pipeline Drugs - Overview by Mechanism of Action
      • Pipeline Drugs - Overview by Route of Administration
      • Pipeline Drugs - Drug-Specific PTSRs and LoA in Sarcopenia
      • Clinical Trials in Sarcopenia - Historical Overview
      • Clinical Trials in Sarcopenia - Overview by Phase
      • Clinical Trials in Sarcopenia - Overview by Status
      • Clinical Trials in Sarcopenia - Overview of Ongoing and Planned Trials by Phase
      • Clinical Trials in Sarcopenia - Trials with a Virtual Component
      • Clinical Trials in Sarcopenia - Geographic Overview
      • Clinical Trials in Sarcopenia - Single-Country and Multinational Trials by Region
      • Clinical Trials in Sarcopenia - Top 20 Sponsors with Breakdown by Phase
      • Clinical Trials in Sarcopenia - Top 20 Sponsors with Breakdown by Status
      • Clinical Trials in Sarcopenia - Overview by Endpoint Status
      • Clinical Trials in Sarcopenia - Overview by Race and Ethnicity
      • Clinical Trials in Sarcopenia - Enrollment Data
      • Clinical Trials in Sarcopenia - Overview of Sites by Geography
      • Clinical Trials in Sarcopenia - Top 20 Countries for Trial Sites
      • Clinical Trials in Sarcopenia - Top 20 Sites Globally
      • Clinical Trials - Feasibility Analysis: Geography Overview
      • Clinical Trials - Feasibility Analysis: Benchmark Models for Sarcopenia
      • Deals Landscape - Mergers, Acquisitions, and Strategic Alliances in Sarcopenia by Region
      • Deals Landscape - Recent Mergers, Acquisitions, and Strategic Alliances in Sarcopenia
      • Commercial Assessment - Key Market Players in Sarcopenia
      • Future Market Catalysts - Upcoming Market Catalysts in Sarcopenia
      • Methodology
      • Methodology - PTSR and LoA Analysis

    Pricing

    Currency Rates
    How Do Licenses Work?

    How Do Licenses Work?

    The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

    • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

    • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

    • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

    • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

    • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

    License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

    Request A Sample
    Head shot

    Questions or Comments?

    Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
    Chat Now
    Contact Us